American Journal of Epidemiology Vol. 152, No. 3 : 242-246
Copyright © 2000 by The Johns Hopkins University School of Hygiene and Public Health
ORIGINAL CONTRIBUTIONS |
Oral Contraceptives and Benign Ovarian Tumors
1 Department of Obstetrics and Gynecology, and School of Public Health, College of Physicians and Surgeons, Columbia University, New York, NY.
2 Department of Preventive Medicine, Mount Sinai School of Medicine, New York, NY.
3 Department of Epidemiology, University of North Carolina, Chapel Hill, NC.
4 Department of Pathology, College of Physicians and Surgeons, Columbia University, New York, NY.
5 Department of Health Research and Policy, Stanford University, Stanford, CA.
Whether use of combined oral contraceptives (OC) protects against benign ovarian tumors is unknown. A case-control study of pathologically confirmed benign ovarian tumors was conducted in the New York City area and included cases diagnosed from January 1, 1992, to December 31, 1993, and controls identified by random digit dialing. There were 196 cases with serous adenomas, 176 with teratomas, 311 with endometriomas, and 65 with mucinous adenomas. Interview data were used to determine contraceptive use. Ever use of OC was associated with a decreased risk of these benign tumors (age- and hospital-adjusted odds ratio = 0.79, 95% confidence interval: 0.60, 1.05). In histologic subgroup analyses, the risk of ovarian tumors was reduced for both current and past OC users. Among tumor subtypes, the risk reduction was greatest for women who had endometriotic lesions. The risk reduction also was greater for women who had used OC for more than 24 months. Protection against benign ovarian tumors may be an additional noncontraceptive benefit of OC use. Am J Epidemiol 2000;152:242–6.
adenoma; contraceptives; oral; endometriosis; ovarian neoplasms; teratoma
Abbreviations: OC, combined oral contraceptives.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. J. Jordan, A. C. Green, D. C. Whiteman, P. M. Webb, for the Australian Ovarian Cancer Study Group, and the Australian Cancer Study (Ovarian Cancer) Risk Factors for Benign Serous and Mucinous Epithelial Ovarian Tumors Obstet. Gynecol., March 1, 2007; 109(3): 647 - 654. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Guharoy and J. Noviasky Ethical beliefs and professional duty Am. J. Health Syst. Pharm., September 15, 2005; 62(18): 1864 - 1866. [Full Text] [PDF]
|
|
|
|
 |
|
 The ESHRE Capri Workshop Group Noncontraceptive health benefits of combined oral contraception Hum. Reprod. Update, September 1, 2005; 11(5): 513 - 525. [Abstract] [Full Text] [PDF]
|
|